argenx - ARGX Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.

15 Wall Street analysts have issued 1 year price targets for argenx's shares. Their ARGX share price forecasts range from $420.00 to $480.00. On average, they expect the company's stock price to reach $453.23 in the next year. This suggests a possible upside of 22.2% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.

argenx's stock was trading at $378.83 at the beginning of the year. Since then, ARGX stock has decreased by 2.1% and is now trading at $370.95.
View the best growth stocks for 2023 here.

argenx saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 777,900 shares, a decline of 6.7% from the December 31st total of 834,000 shares. Based on an average trading volume of 252,000 shares, the short-interest ratio is presently 3.1 days.
View argenx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ARGX earnings forecast.

argenx SE (NASDAQ:ARGX) released its quarterly earnings data on Wednesday, October, 27th. The company reported ($4.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.48) by $0.38. The company earned $7.11 million during the quarter, compared to analysts' expectations of $20 million. argenx had a negative net margin of 295.08% and a negative trailing twelve-month return on equity of 66.04%. During the same period last year, the company earned ($3.96) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx trades on the NASDAQ under the ticker symbol "ARGX."

argenx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.24%), New York State Common Retirement Fund (0.21%), Allspring Global Investments Holdings LLC (0.13%), Bank of Montreal Can (0.12%), Tobam (0.05%) and Mckinley Capital Management LLC Delaware (0.04%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARGX stock can currently be purchased for approximately $370.95.

argenx (NASDAQ:ARGX) has a market capitalization of $20.55 billion and generates $539.42 million in revenue each year. The company earns $-408,270,000.00 in net income (profit) each year or ($17.19) on an earnings per share basis.

The company employs 650 workers across the globe.

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.